TY - JOUR
T1 - Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan
AU - Wu, I.-T.
AU - Chuah, S.-K.
AU - Lee, Chih-Hung
AU - Liang, C.-M.
AU - Lu, L.-S.
AU - Kuo, Y.-H.
AU - Yen, Y.-H.
AU - Hu, M.-L.
AU - Chou, Y.-P.
AU - Yang, S.-C.
AU - Kuo, C.-M.
AU - Kuo, C.-H.
AU - Chien, C.-C.
AU - Chiang, Y.-S.
AU - Chiou, S.-S.
AU - Hu, T.-H.
AU - Tai, W.-C.
PY - 2015
Y1 - 2015
N2 - AIM: To determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy. METHODS: We analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively. RESULTS: A high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend. CONCLUSION: Antibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.
AB - AIM: To determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy. METHODS: We analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively. RESULTS: A high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend. CONCLUSION: Antibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.
KW - Antibiotic resistance
KW - Antibiotic resistance
KW - Failed first-line therapy
KW - Failed first-line therapy
KW - Five-year sequential changes
KW - Five-year sequential changes
KW - Helicobacter pylori
KW - Helicobacter pylori
KW - Southern Taiwan
KW - Southern Taiwan
U2 - 10.3748/wjg.v21.i37.10669
DO - 10.3748/wjg.v21.i37.10669
M3 - Journal Article
C2 - 26457027
SN - 1007-9327
VL - 21
SP - 10669
EP - 10674
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
IS - 37
ER -